F2RL1 and hyperuricemia: We found that AZ3451 (a selective metabotropic antagonist of PAR2) inhibited hyperuricemia-mediated activation of the PI3K/AKT/NF-κB pathway and attenuated the interstitial inflammatory response and renal tissue injury, which reduced the expression of inflammation-associated cytokines.